Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ascendis Pharma Ads (ASND)

Ascendis Pharma Ads (ASND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address significant unmet medical needs, will provide an outlook for 2020 and review...

JPM : 138.20 (+0.69%)
ASND : 139.13 (-0.95%)
Ascendis Pharma A/S Announces Participation in 38th Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will participate...

JPM : 138.20 (+0.69%)
ASND : 139.13 (-0.95%)
Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results

- Continued execution of global endocrinology rare disease programs as planned regulatory filings for TransCon(TM) hGH in 2020 advance on track -

ASND : 139.13 (-0.95%)
New Records and New Milestones

New Records and New Milestones

FTNT : 117.49 (-1.34%)
PAYC : 296.24 (+0.66%)
VXX : 13.32 (+0.23%)
GWPH : 118.97 (-0.13%)
ASND : 139.13 (-0.95%)
TRWH : 25.81 (-0.69%)
VAPO : 12.28 (+2.93%)
Ascendis Pharma Expands TransCon(TM) PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA(R) in the United States

- Reflects company values and commitment to patients living with hypoparathyroidism -

ASND : 139.13 (-0.95%)
What's in Store for Helmerich & Payne (HP) in Q4 Earnings?

Helmerich & Payne's (HP) much popular technologically-advanced FlexRigs with strong daily rate margins might reflect on segmental profits in the to-be-reported results.

BMO : 79.42 (+0.18%)
ASND : 139.13 (-0.95%)
HP : 45.13 (-0.27%)
CGC : 24.89 (+2.43%)
5 Biotech Stocks Set to Beat Q3 Earnings Estimates

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

ASND : 139.13 (-0.95%)
SAGE : 76.40 (+3.12%)
NGM : 18.90 (-0.47%)
EYEN : 4.73 (-3.86%)
ACIU : 9.20 (-5.25%)
Ascendis Pharma A/S Announces Upcoming Investor Presentation in November

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will participate...

ASND : 139.13 (-0.95%)
Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon(TM) Technology in Oncology at SITC 2019

- A single dose of TransCon TLR7/8 Agonist demonstrated sustained localized release of active drug over weeks and potent anti-tumor activity when administered directly into the tumor -

ASND : 139.13 (-0.95%)
CannTrust (CTST) to Report Q3 Earnings: What's in Store?

On CannTrust's (CTST) third-quarter earnings call, investor focus will be on the company's efforts to regain licenses for producing and selling cannabis.

FOLD : 10.41 (-1.42%)
ASND : 139.13 (-0.95%)
CTST : 1.18 (+0.85%)
EYEN : 4.73 (-3.86%)
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?

Zoetis (ZTS) is expected to provide pipeline updates during the third-quarter earnings call.

FOLD : 10.41 (-1.42%)
ASND : 139.13 (-0.95%)
ZTS : 140.16 (+0.66%)
EYEN : 4.73 (-3.86%)
Ascendis Pharma A/S Announces Third Quarter 2019 Financial Results and Business Update Conference Call on November 18

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will hold a conference...

ASND : 139.13 (-0.95%)
Ascendis Pharma A/S (ASND) Upgraded to Buy: Here's Why

Ascendis Pharma A/S (ASND) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ASND : 139.13 (-0.95%)
Ascendis Pharma A/S Receives Orphan Designation for TransCon(TM) hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the European Commission (EC) has granted...

ASND : 139.13 (-0.95%)
Ascendis Pharma A/S Announces Upcoming Investor Presentation in October

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will participate...

ASND : 139.13 (-0.95%)
Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon(TM) CNP at International Skeletal Dysplasia Society Meeting

- TransCon CNP program gains momentum with initiation of phase 2 ACcomplisH Trial -

ASND : 139.13 (-0.95%)
Ascendis Pharma A/S Announces Three Investor Presentations in September

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will participate...

ASND : 139.13 (-0.95%)
Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results

- TransCon hGH moves towards Biologics License Application submission following completion of heiGHt and fliGHt Trials -

ASND : 139.13 (-0.95%)
Ascendis Pharma A/S Announces Second Quarter 2019 Financial Results and Business Update Conference Call on August 28

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will hold a conference...

ASND : 139.13 (-0.95%)
Ascendis Pharma A/S Announces Participation in August Investor Conferences

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will participate...

ASND : 139.13 (-0.95%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -0.35 , SEDG +2.05 , THC unch , TER -0.21 , LITE -0.79
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar